Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Research Grade Ligelizumab (HV064026)

Research Grade Ligelizumab
Research Grade Ligelizumab
Research Grade Ligelizumab
Research Grade Ligelizumab
価格(USD): $
スペック:
  • 100ug
  • 1mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

概要
カタログ番号HV064026
説明
Ligelizumab (HV064026) is a research-grade recombinant antibody targeting Ig epsilon chain C region. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性Human
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Humanized
アイソタイプIgG1-kappa
発現システム Mammalian Cells
クローン性 Monoclonal
ターゲット Ig epsilon chain C region, IGHE, Ig epsilon chain C region ND, Immunoglobulin heavy constant epsilon
エンドトキシンレベル Please contact the lab for this information.
純度 >95% purity as determined by SDS-PAGE.
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 P01854
形態 Liquid
保存バッファー 0.01M PBS, pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
別名CL-2C, 1322627-61-1
背景

Immunoglobulin heavy constant epsilon (IgE/IGHE) is a ~59 kDa protein. Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens. The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain.

1. Schroeder, HW. et al. (2010) The Journal of allergy and clinical immunology 125, S41-52. PMID: 20176268
2. McHeyzer-Williams, M. et al. (2011) Nature reviews. Immunology 12, 24-34. PMID: 22158414
3. Teng, G. et al. (2007) Annual review of genetics 41, 107-20. PMID: 17576170
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • Research Grade Ligelizumab

    Bioactivity

    SEC-HPLC detection for Research Grade Ligelizumab.

  • Research Grade Ligelizumab

    SDS-PAGE

    SDS-PAGE for Research Grade Ligelizumab.

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: support@abinScience.com

ディストリビューターリスト